Response to: Safety and efficacy considerations of HSC-based gene therapy for RAG1-deficient SCID. Montini E, Naldini L, Booth C, Kohn DB, Aiuti A. Mol Ther. 2025 May 7;33(5):1871. doi: 10.1016/j.ymthe.2025.03.049. Epub 2025 Apr 15. PMID: 40233756